
Gwyneth Paltrow Opened Up About How Her Menopause Symptoms Got "Out Of Control" After She Turned To Alcohol To Cope Amid The Devastating LA Wildfires
Gwyneth Paltrow has opened up about how she coped amid the devastating Los Angeles wildfires.
On a recent episode of The Goop Podcast, Gwyneth sat down for a conversation titled 'What No One Ever Told Us About Menopause.' She was joined by guest Dr. Mary Claire Haver — a board-certified OB/GYN and author of the New York Times bestseller The New Menopause.
As they began discussing their own experiences with menopausal symptoms currently, Gwyneth, 52, shared, 'I'm really in the thick of it right now, so I'm all over the place.'
'But I noticed my symptoms are like, pretty well under control — unless, you know, in January when the fires were happening in LA,' she continued. 'I've used alcohol for its purpose.'
'I was medicating,' Gwyneth explained before admitting that during "those two weeks I think I drank every night' amid the fires.
Gwyneth went on to explain that her menopausal symptoms were 'completely out of control' due to her increased use of alcohol. 'Now at this point, I don't drink a lot at all,' she said. 'Maybe I'll have one drink a week.'
While Gwyneth and her family were thankfully not directly impacted by the LA wildfires back in January, she shared on Instagram at the time that 'so many of [her] close friends have lost everything,' and that she was experiencing a 'deep grief.'
On her drinking impacting her menopausal symptoms, Gwyneth concluded, 'It was the first time I really noticed, like, causation in that way.'
Dr. Haver offered a confirmation of Gwyneth's suspicions, saying, 'Lots of my patients say the same thing. They've really just spontaneously realized that they've cut back on alcohol or just quit altogether because it hasn't been worth it. They don't bounce back the same way. It stays in our system a lot longer."
Gwyneth also shared that she's currently 'making an effort' to switch her mindset around eating from what it's been in the past. When Dr. Haver spoke about how she's trying to 'eat to be strong instead of eat to be thin,' Gwyneth opened up about her own challenges.
'It's tough. It's hard,' Gywneth said in reference to eating more protein, saying that her generation 'was raised' to value being thin over being strong. 'I mean, I'm making a real effort to do it, I'm really trying but sometimes I'm like gagging down cottage cheese — I know that it's necessary, but…' she said, to which Dr. Haver agreed.
The Iron Man star has previously faced scrutiny for her comments surrounding her diet. Back in 2023, Gwyneth received a ton of backlash for describing her diet that seemingly consisted of primarily bone broth and vegetables. At the time, her revelation prompted people to argue that she was promoting unhealthy eating habits.
She then responded, saying, 'This was a transparent look at a conversation between me and my doctor. It's not meant to be advice for anybody else. It's really just what has worked for me and it's been very powerful and very positive.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
SAN CARLOS, Calif., June 11, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, will provide an update on BeOne's extensive global innovation pipeline and platforms, including new assets, targets and clinical data, and will share insights on the Company's vision, differentiated capabilities, and value creation drivers. Live webcast of this event can be accessed from the investors section of the Company's website at To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law. View source version on Contacts Investors: Liza Heapes+1 857-302-5663ir@ Media: Kyle Blankenship+1 667-351-5176media@
Yahoo
9 hours ago
- Yahoo
Landfill summit calls for homes to be 'safe space'
A father whose seven-year-old son died during severe floods says homes "should always be a safe space" on the day of a summit about toxic landfills. Campaigners from more than 20 communities experiencing "severe and sometimes fatal harms from toxic landfill and contaminated water" will speak at Wednesday's Zane's Law summit, organisers said. They include Kye and Nicole Gbangbola, whose son Zane died after the River Thames flooded their Surrey home in 2014. His parents disputed the results of an inquest in 2016 and say their son was killed by gas washed out of a former landfill site in Chertsey. At his inquest, the coroner concluded Zane was killed by carbon monoxide from a petrol pump used to clear flood water from the family home in Chertsey. Zane's parents will join Dirty Water Campaign, Gas Communities United, Corby Childhood Cancer, and the Environment Secretary Steve Reed at a gathering at the Houses of Parliament. The coalition of landfill campaigns have come together calling for Zane's law, which Mr Gbangbola described as "enforceable law to protect communities from the dangers of toxic landfill and polluted water". Other speakers will include Des Collins, the solicitor who represented families affected by the toxic waste scandal in Corby, dramatised in the recent Netflix series Toxic Town. Mr Gbangbola told BBC Radio Surrey the summit would bring together campaigns from "all across the country that up until this point have really been unheard". "When they come together they move through an understanding that it's not only them, there's others across the country, other communities experiencing such harm and death," he added. He claimed the issues of those living near toxic landfills ranged from respiratory issues, through to birth defects, tumours, neurological and immune system damage and homes which could be valued at zero. "Our homes should always be a safe space, when you're experiencing these impacts simply from living in proximity to landfill it becomes a time when action is needed," he said. Baroness Natalie Bennett, who will chair the hybrid meeting, said current UK regulations on contaminated land were "grossly inadequate" and a threat to the safety of many. Several local authorities have passed motions calling for Zane's Law. The Department for Environment, Food & Rural Affairs has been contacted for comment. Follow BBC Surrey on Facebook, on X, and on Instagram. Send your story ideas to southeasttoday@ or WhatsApp us on 08081 002250. Calls for independent inquiry into boy's death 'He was born navy blue': Real-life stories behind Toxic Town Netflix series Concern over experiments near home of boy who died Judicial review over 'contaminated' land claim Son's death cover-up like Post Office scandal - dad Department for Environment, Food & Rural Affairs
Yahoo
9 hours ago
- Yahoo
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Filament Health Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data